Tang Jia-ming, Meng Fan-yi, Ma Wen-li
Department of Hematology, Nanfang Hospital, Nanfang Medical University, Guangzhou 510515, China.
Zhonghua Xue Ye Xue Za Zhi. 2005 Nov;26(11):653-5.
To investigate the mechanism of refractoriness of acute myeloid leukemia (AML) by studying the changes of gene mRNA expression from primary diagnosis to relapsed disease in AML.
Differences in gene expression profile of bone marrow mononuclear cells were compared between primary diagnosis and relapsed/refractory disease in 3 patients with M(2a) subtype of AML using Agilent human 1B 60mer oligonucleotide microarray.
Common alterations were found in 10 genes among the 20173 genes tested at relapsed/refractory disease as compared with that at primary diagnosis in 3 patients. Of these 10 genes, 7 were up-regulated while 3 down-regulated at relapse in all the 3 patients.
Development of relapsed/refractory disease in AML-M(2a) might be associated with the mRNA expression changes in the 10 genes tested including DAPK1. The alteration of these genes may be indications for the early diagnosis of refractoriness of AML, and these genes might provide new therapeutic targets for the treatment of refractory AML.
通过研究急性髓系白血病（AML）从初诊到复发疾病过程中基因mRNA表达的变化，探讨AML难治性的机制。
使用安捷伦人类1B 60mer寡核苷酸微阵列，比较3例M（2a）亚型AML患者初诊与复发/难治性疾病时骨髓单个核细胞基因表达谱的差异。
与3例患者初诊时相比，在复发/难治性疾病时检测的20173个基因中，发现10个基因有共同改变。在这10个基因中，所有3例患者复发时7个基因上调，3个基因下调。
AML-M（2a）复发/难治性疾病的发生可能与包括DAPK1在内的10个检测基因的mRNA表达变化有关。这些基因的改变可能是AML难治性早期诊断的指标，并且这些基因可能为难治性AML的治疗提供新的治疗靶点。
